Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.42 |
| ▸ | ALDH1A2 | O94788 | 3/20 | 0.42 |
| ▸ | ALDH1B1 | P30837 | 3/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6995788 | 0.83 | KMT2A (0.50) | KMT2AKDM4ETSHRALDH1A1ALDH2 | |
| SCHEMBL29563811 | 0.82 | KMT2A (0.61) | KMT2AKDM4ETSHRALDH1A1ALDH2 | |
| SCHEMBL6995672 | 0.78 | KMT2A (0.45) | KMT2AKDM4ETSHRALDH1A1ALDH2 | |
| SCHEMBL6991055 | 0.78 | KMT2A (0.45) | KMT2AKDM4ETSHRALDH1A1ALDH2 | |
| Hydrochloric Acid SCHEMBL6995179 | 0.77 | KMT2A (0.44) | KMT2AKDM4ETSHRALDH1A1ALDH2 | |
| SCHEMBL6999492 | 0.75 | KMT2A (0.41) | KMT2AKDM4ETSHRALDH1A1ALDH2 | |
| SCHEMBL18788609 | 0.69 | KMT2A (1.00) | KMT2AKDM4ETSHRALDH1A1ALDH2 | |
| SCHEMBL6802035 | 0.64 | ALDH1A1 (0.70) | KDM4ETSHRALDH1A1MAPTKCNA3 | |
| SCHEMBL20036256 | 0.64 | ALDH1A1 (0.64) | KDM4ETSHRALDH1A1MAPTKCNA3 | |
| SCHEMBL16904135 | 0.62 | ALDH1A1 (0.54) | KMT2AKDM4EALDH1A1MAPTMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032265-B1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030082510-A1 | Psoralens for pathogen inactivation | CERUS CORPORATION (US) | 2003-05-01 | — | — | US | disclosed |
| US-6455286-B1 | MIXING PSORALEN COMPOUND OF DEFINED STRUCTURE WITH BIOLOGICAL COMPOSITION SUCH AS BLOOD OR PLATELETS, THEN PHOTOACTIVATING COMPOUND TO DEACTIVATE PATHOGEN | CERUS CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-6133460-A | HAVE PRIMARY AMINO SUBSTITUTIONS ON THE 3-, 4-, 5-, AND 8-POSITIONS OF THE PSORALEN WHICH PERMIT BINDING TO NUCLEIC ACID OF PATHOGENS; CONDITIONS THAT PHOTOACTIVATE THESE PSORALENS RESULT IN INACTIVATION OF PATHOGENS WHICH CONTAIN NUCLEIC ACID | CERUS CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082510-A1 | Psoralens for pathogen inactivation | BPGM, XPA, RAD50 | KMT2A 2413/4885KDM4E 3035/4885TSHR 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.